A Class of 5-Nitro-2-furancarboxylamides with Potent Trypanocidal Activity againstTrypanosoma bruceiin Vitro
Citations Over TimeTop 10% of 2013 papers
Abstract
Recently, the World Health Organization approved the nifurtimox-eflornithine combination therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheterocycle therapies for this and associated diseases. In this study, we have synthesized a series of novel 5-nitro-2-furancarboxylamides that show potent trypanocidal activity, ∼1000-fold more potent than nifurtimox against in vitro Trypanosoma brucei with very low cytotoxicity against human HeLa cells. More importantly, the most potent analogue showed very limited cross-resistance to nifurtimox-resistant cells and vice versa. This implies that our novel, relatively easy to synthesize and therefore cheap, 5-nitro-2-furancarboxylamides are targeting a different, but still essential, biochemical process to those targeted by nifurtimox or its metabolites in the parasites. The significant increase in potency (smaller dose probably required) has the potential for greatly reducing unwanted side effects and also reducing the likelihood of drug resistance. Collectively, these findings have important implications for the future therapeutic treatment of African sleeping sickness.
Related Papers
- → Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes(2015)6 cited
- → Evaluating 5-Nitrofurans as Trypanocidal Agents(2013)38 cited
- → Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors(2017)20 cited
- [Effect of quinones and nitrofurans on Trypanosoma mega and Crithidia fasciculata].(1989)
- → Enzymatic formation of prostaglandin D2, E2, and F2α in the parasitic protozoan Trypanosoma brucei(2002)3 cited